Showing 4481-4490 of 5910 results for "".
- New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at ARVOhttps://modernod.com/news/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-to-be-presented-at-arvo/2480815/Opus Genetics announced that data from two preclinical studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5 or RDH12 genes, respectively, will b
- Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During ARVOhttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo/2480814/Bausch + Lomb announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colorado, from May 1-4, 2022, and virtually from May 11-12, 2022. The presentations incl
- Recent Alimera Data Featured in Scientific Programming at ARVOhttps://modernod.com/news/recent-alimera-data-featured-in-scientific-programming-at-arvo/2480813/Alimera Sciences announced today that Iluvien will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.
- Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission of Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-of-nyxol-for-reversal-of-mydriasis/2480812/Ocuphire Pharma announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). The results demonstrated that Nyxol’s efficacy and safety in pediatric subjects 3-11 ye
- Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meetinghttps://modernod.com/news/graybug-to-present-preclinical-data-for-gb-401-in-primary-open-angle-glaucoma-at-the-2022-arvo-annual-meeting/2480808/Graybug Vision announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 20
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480806/Allegro Ophthalmics announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ARVO 2022 will be held May 1-4, 2022 in
- Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480805/Visus Therapeutics announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on Brimochol PF, th
- Apellis Announces Results from New Survey Revealing the Emotional Burden Caused by Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-results-from-new-survey-revealing-the-emotional-burden-caused-by-geographic-atrophy-ga/2480801/Apellis Pharmaceuticals announced results from a global survey conducted by The Harris Poll, which found that living with geographic atrophy (GA) can cause a substantial emotional burden and impact on independence. GA is a leading cause of blindness that affects more than 5 million people wo
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Ocular Therapeutix to Present Preclinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2480797/Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting being held May 1-4 in Denver, Colorado and May 11-12 virtually. “At this year’s annual meeting, we are thrilled to be presenting c